anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
MindMed · conference-presentation

MindMed | Results Presentation Deck | 40 slides

40 pages · 5 arc beats · 3 loops

Conference-Presentation Download JSON
Unlock

MindMed | Results Presentation Deck | 40 slides

MindMed · 2022-05
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 30 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 4 slides 100% 4/4 slides 100% 4/4 slides · 18 hits
— 0/4 slides
50% 2/4 slides 75% 3/4 slides 100% 4/4 slides 100% 4/4 slides Agitate 2 slides 100% 2/2 slides 100% 2/2 slides · 9 hits
— 0/2 slides
50% 1/2 slides 50% 1/2 slides 100% 2/2 slides 100% 2/2 slides Solution 17 slides 100% 17/17 slides 100% 17/17 slides · 81 hits
— 0/17 slides
70.6% 12/17 slides · 13 hits 29.4% 5/17 slides 100% 17/17 slides 52.9% 9/17 slides Evidence & Proof 4 slides 100% 4/4 slides 100% 4/4 slides · 21 hits
— 0/4 slides
— 0/4 slides
— 0/4 slides
100% 4/4 slides 100% 4/4 slides Impact & Next Steps 3 slides 100% 3/3 slides 100% 3/3 slides · 12 hits
— 0/3 slides
— 0/3 slides
33.3% 1/3 slides 100% 3/3 slides
— 0/3 slides

Slide inventory

40
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
front_matter
Open slide detail
04
summarize
Open slide detail
05
The slide uses a 3x3 matrix structure to categorize drug development strategy by generation (Classic, 2nd Gen/Optimized, 3rd Gen/NCEs).present_framework
Open slide detail
06
The chart uses horizontal bars to indicate the current development stage of various drug candidates.plan_implementation
Open slide detail
07
The slide uses a Gantt-style layout to map clinical trial phases against a timeline.plan_implementation
Open slide detail
08
other
Open slide detail
09
introduce_nominees
Open slide detail
10
Includes institutional branding for Johns Hopkins Bayview and Maryland Opioid Research (MOR).front_matter
Open slide detail
11
The chart illustrates the escalating mortality rates associated with different categories of drugs over time.analyze_data
Open slide detailBeat · ProblemLoop · Cost Of Inaction
12
The slide uses a shaded area for acute withdrawal and a dashed line for protracted withdrawal, mapped against time intervals for short-acting and long-acting oppresent_framework
Open slide detailBeat · ProblemLoop · Cost Of Inaction
13
The slide uses a simple process-flow diagram to categorize treatment options.present_framework
Open slide detailBeat · ProblemLoop · Cost Of Inaction
14
The chart illustrates the divergence between OUD prevalence and treatment capacity over time (2003-2012).expose_gap
Open slide detailBeat · ProblemLoop · Cost Of Inaction
15
The chart illustrates a clear divergence between maintenance and supervised withdrawal regarding the use of opioid agonists.diagnose_problem
Open slide detailBeat · AgitateLoop · Cost Of Inaction
16
Includes a citation of a specific academic paper on non-opioid neurotransmitter systems.present_solution
Open slide detailBeat · AgitateLoop · Cost Of Inaction
17
The slide introduces a chemical compound (18-MC) and its relationship to ibogaine, highlighting a distinct mechanism of action and potential safety benefits.establish_context
Open slide detailBeat · SolutionLoop · Trojan Horse
18
Source: Glick & Maisonneuve, 2000. The slide uses two different chart types (line and bar) to demonstrate the same pharmacological effect.analyze_data
Open slide detailBeat · SolutionLoop · Trojan Horse
19
The slide uses a bar chart to demonstrate the specificity of 18-MC compared to Ibogaine in a pharmacological study.summarize
Open slide detailBeat · SolutionLoop · Trojan Horse
20
Slide contains two distinct charts labeled A and B, referencing specific research papers.analyze_data
Open slide detailBeat · SolutionLoop · Trojan Horse
21
The slide displays 7 distinct bar charts representing different withdrawal symptoms (Weight Loss, Wet-Dog Shakes, Flinching, Grooming, Teeth Chattering, Buryinganalyze_data
Open slide detailBeat · SolutionLoop · Trojan Horse
22
The chart highlights specific withdrawal symptoms (Wet-Dog Shakes, Teeth Chattering, Burying, Diarrhea) that show statistically significant reductions with 18-Manalyze_data
Open slide detailBeat · SolutionLoop · Trojan Horse
23
compare_peers
Open slide detailBeat · SolutionLoop · Trojan Horse
24
The slide uses a 'So Why Now?' framing to justify the relevance of the topic.establish_context
Open slide detailBeat · SolutionLoop · Trojan Horse
25
The table uses color coding (yellow for TBD/preclinical, green for established/favorable) to highlight the developmental status of 18-MC versus the established compare_peers
Open slide detailBeat · SolutionLoop · Trojan Horse
26
summarize
Open slide detailBeat · Solution
27
The slide outlines a timeline of clinical trial events for the drug candidate MM-110.plan_implementation
Open slide detailBeat · Solution
28
The slide uses a combination of a longitudinal bar/line chart and key metrics to quantify the problem.diagnose_problem
Open slide detailBeat · Solution
29
The slide uses a line chart metaphor to represent patient state/cravings over time, highlighting the intervention point of MM-110.present_solution
Open slide detailBeat · Solution
30
The slide presents preclinical efficacy data for MM-110 using bar and line charts.analyze_data
Open slide detailBeat · Solution
31
The slide presents data from Rho & Glick (1998) showing dose-dependent reduction in withdrawal behaviors.analyze_data
Open slide detailBeat · Solution
32
The chart compares saline vs. Methoxycoronaridine (MM-110) across 6 time points (Base, Day 1, 2, 3, 6, 7).analyze_data
Open slide detailBeat · Solution
33
summarize
Open slide detailBeat · Solution
34
SAD = Single Ascending Dose; MAD = Multiple Ascending Dose. Data shows n (%) of participants experiencing safety events.analyze_data
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
35
Data presented as n (%). SOC and PT assigned using MedDRA version 23.0.analyze_data
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
36
SAD = Single Ascending Dose, MAD = Multiple Ascending Dose. Data presented as n (%).analyze_data
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
37
Data represents cohorts 12 and 15 of MMED003 study.analyze_data
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
38
Data shown are means, n=5 (Cohort 14 of Study MMED003) using validated LC-MS/MS assay for zolunicant.analyze_data
Open slide detailBeat · Impact & Next Steps
39
The slide outlines a sequential study design where Part A informs the design of Part B.present_framework
Open slide detailBeat · Impact & Next Steps
40
summarize
Open slide detailBeat · Impact & Next Steps